Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006434.
Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.
细胞治疗涵盖了一系列基于细胞的治疗方法，用于治疗人类疾病，例如使用免疫细胞，特别是 T 细胞，来对抗肿瘤和调节炎症性免疫反应。在这篇综述中，我们专注于免疫肿瘤学领域的细胞治疗，这主要是由于临床对更好的解决方案的兴趣和需求，以针对各种难治性癌症。我们讨论了各种类型的细胞治疗的最新进展，包括 T 细胞受体-T 细胞、嵌合抗原受体 (CAR)-T 细胞、肿瘤浸润淋巴细胞和自然杀伤细胞。特别是，本综述重点讨论了通过增强肿瘤识别或增强在肿瘤微环境中输注的免疫细胞的弹性来提高治疗反应的策略。最后，我们讨论了目前正在探索的其他先天或先天样免疫细胞类型的潜力，这些细胞类型被认为是有前途的 CAR 细胞替代物，旨在解决传统过继细胞治疗的局限性。
